Abstract Library

#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,

Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,

#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone

Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Chan B, Wyld D, Burge M, Cuneo R, Macfarlane D,

Keywords: pancreatic, neuroendocrine, tumor, ACTH, everolimus, pasireotide, lutetium,

#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor

Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Brizzi M, Ferrero A, Ottone A, Bellini E, Bitossi R,

Keywords: paraneoplastic syndrome,

#472 Detection of Liver Metastases and Prognostic Value of Functional and Anatomical Imaging in Patients with Neuroendocrine Tumors

Introduction: Liver metastases (LM) are frequent in patients with neuroendocrine tumors (NETs) and are associated with decreased overall survival (OS). Several treatment options are available depending on degree, localization, size and number of LM. For optimal choice of treatment and correct staging, accurate imaging modalities are crucial.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Knigge U, Binderup T, Federspiel B, Palnæs Hansen C, Loft A,

Keywords: ,

#393 Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Differential Response of Bone Versus Soft Tissue Lesions

Introduction: Little is known about the treatment response of bone lesions to treatment with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Van Vliet E, Hermans J, De Ridder M, Teunissen J, Kam B,

Keywords: gep-net, PRRT, treatment response, bone metastases,